We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Plasma product companies outmuscle small recombinant players.
- Authors
Mitchell, Peter
- Abstract
The article examines how small biotechnology companies that market recombinant therapeutic proteins are having a difficult time competing against large companies that have segued into recombinant technology. These larger companies often have more experience in dealing with hospital procurement systems, making it difficult for smaller firms to establish their products. Recombinant therapies have become a lucrative market through such developments as recombinant insulin, interferon alpha and human growth hormone. This technology is contrasted with commercially limited therapeutic proteins. The purchase of the plasma product company Talecris Biotherapeutics by the Australian plasma product firm CSL is discussed.
- Subjects
BIOTECHNOLOGY; SMALL business -- Social aspects; BIG business; RECOMBINANT proteins; HUMAN growth hormone; INSULIN structure; THERAPEUTIC use of interferons; TALECRIS Biotherapeutics Inc.; CSL Behring LLC; THERAPEUTICS
- Publication
Nature Biotechnology, 2008, Vol 26, Issue 10, p1060
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt1008-1060c